NCT03893643 Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15
| NCT ID | NCT03893643 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Nice |
| Condition | Neurofibromatosis 2 |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2019-01-01 |
| Primary Completion | 2022-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2019-01-01 with a primary completion date of 2022-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
.Neurofibromatosis type 2 is an inherently autosomal dominant genetic disease, but cases of mosaicism or de novo mutation are not uncommon. the prevalence is estimated at 1 / 60,000. the clinical presentation is based on the appearance of tumors in the central and peripheral nervous system. The current average age of diagnosis is around 25 to 30 years depending on the studies. Currently, the diagnostic criteria are based on the ENT, neurological and opthalmological manifestations of the disease. Cutaneous manifestations have been described in these patients. Except now, mucocutaneous manifestations of the disease are not taken into account for depisatage or diagnosis. The purpose of this study would be to identify the different cutaneous and mucosal manifestations in a pediatric population under 15 years of age, and to analyze whether this might be of interest in early detection of the disease in association with other symptoms.
Eligibility Criteria
Inclusion Criteria: * age up to 15 years * diagnosis of neurofibromatosis type 2 Exclusion Criteria: * refusal to participate in the study * informed consent that can not be obtained because of a disability or difficulties with a - language barrier
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03893643 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 15 Years, studying Neurofibromatosis 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03893643 currently recruiting?
Yes, NCT03893643 is actively recruiting participants. Contact the research team at sophie.legoupil@hotmail.fr for enrollment information.
Where is the NCT03893643 trial being conducted?
This trial is being conducted at Nice, France.
Who is sponsoring the NCT03893643 clinical trial?
NCT03893643 is sponsored by Centre Hospitalier Universitaire de Nice. The trial plans to enroll 1,000 participants.